Stocks to Watch Today (Nov. 10, 2025): Nvidia Rebounds; Pfizer Clinches Metsera; Novo Nordisk Rises; Rumble Soars on AI Deal; Tyson Foods Guides Higher
10 November 2025
2 mins read

Stocks to Watch Today (Nov. 10, 2025): Nvidia Rebounds; Pfizer Clinches Metsera; Novo Nordisk Rises; Rumble Soars on AI Deal; Tyson Foods Guides Higher

Published: November 10, 2025

Key takeaways

  • U.S. stock futures point higher as Washington inches toward ending the record government shutdown, with AI leaders rebounding ahead of the open. 1
  • Pfizer wins the $10B bidding war for Metsera; Novo Nordisk bows out and shares climb in Copenhagen. 2
  • Rumble jumps after striking an all‑stock deal to buy Germany’s Northern Data, adding tens of thousands of Nvidia GPUs and a Tether-backed leasing pact. 3
  • Tyson Foods posts Q4 results and guides FY2026 revenue higher as chicken offsets beef headwinds. 4

Market snapshot: AI leads early rebound

U.S. index futures moved higher Monday as Senate action over the weekend boosted hopes for a stopgap funding bill to end the record federal shutdown. Nasdaq 100 futures led gains and AI bellwether Nvidia (NASDAQ: NVDA) traded about 3% higher premarket, pacing a broader chip bounce. 1

Adding to the tone, Nvidia CEO Jensen Huang said over the weekend that demand for the company’s next‑gen Blackwell platform remains “very strong,” underscoring continued wafer needs from TSMC. The remarks come as investors look to AI hardware leaders to reassert momentum after last week’s pullback. 5

What’s next: Nvidia’s Q3 FY26 results arrive Wednesday, November 19 after the bell—an event likely to set the near‑term tone for mega‑cap AI. 6


Deal watch: Pfizer takes Metsera in $10B obesity-drug play

Pfizer (NYSE: PFE) sealed a revised agreement to acquire Metsera (NASDAQ: MTSR) for $86.25 per share, including $65.60 in cash plus up to $20.65 via contingent value rights—capping a fast‑moving bidding war with Novo Nordisk (NYSE: NVO). Metsera’s board backed the sweetened deal Friday; closing is expected shortly after a Nov. 13 shareholder vote. 2

Investors repositioned Monday: Novo Nordisk shares rose roughly 3% in early Copenhagen trade after the company exited the contest, while Metsera traded lower in U.S. premarket action. Markets framed Novo’s retreat as disciplined capital allocation in a red‑hot obesity market that’s still crowded with pipeline risk. 7


Social & AI infrastructure: Rumble buys Northern Data

Video platform Rumble (NASDAQ: RUM) agreed to acquire German AI‑cloud operator Northern Data in an all‑stock deal valued around $767 million. Terms include 2.0281 new Rumble Class A shares per Northern Data share, a $150M GPU‑leasing agreement with Tether (an anchor customer), and access to ~22,400 Nvidia GPUs at close. Rumble shares surged more than 25% premarket on the announcement. 3

Why it matters: The move vaults Rumble deeper into AI infrastructure just as compute capacity becomes a competitive moat for model training and inference—potentially opening new revenue lines beyond video. 3


Consumer staples: Tyson leans on chicken, trims beef exposure pain

Tyson Foods (NYSE: TSN) guided FY2026 revenue up 2%–4%, topping the Street’s 2.3% view, as resilient demand for chicken and prepared foods helps blunt historically tight U.S. cattle supplies. Q4 net sales rose to $13.86B (slightly below consensus $13.97B), with chicken volumes +3.8% and beef volumes −8.4% amid record cattle costs. 4

The company said inflation‑weary consumers are cooking more at home, favoring lower‑priced proteins, and noted the long cattle‑cycle timeline before beef supply fully normalizes. 4


Stocks to watch the rest of the day

  • Nvidia (NVDA): Pre‑earnings rebound with fresh CEO commentary on Blackwell demand and supply chain dynamics. Watch for any additional headlines on TSMC capacity. 5
  • Metsera (MTSR), Pfizer (PFE), Novo Nordisk (NVO): Spread trading likely as arbitrageurs price Pfizer’s CVR structure and as Novo investors digest the decision to exit. Key date: Nov. 13 Metsera shareholder meeting. 2
  • Rumble (RUM): Volatility risk remains as investors model GPU monetization, capex needs, and integration timing (deal expected to close Q2 2026). 3
  • Tyson Foods (TSN): Guidance tone skews constructive; watch management color on commodity costs and pricing elasticity into the holiday period. 4

Editor’s note

This article focuses on the topics and tickers highlighted by Bloomberg/WSJ/Seeking Alpha roundups for November 10, 2025—namely Nvidia, Pfizer, Novo Nordisk, Rumble, Metsera, and Tyson Foods—and cross‑references primary reporting and company disclosures published today. Sources are linked inline. 1

Disclosure: This content is for information only and does not constitute investment advice.

Stock Market Today

Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

7 February 2026
Home Depot shares rose 0.7% to $385.15 Friday, trading between $379.10 and $386.37. Investors await a delayed U.S. jobs report Wednesday and CPI data Friday, both postponed by a brief government shutdown. Home Depot reports fourth-quarter earnings Feb. 24. The Dow closed above 50,000 for the first time.
JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

7 February 2026
JPMorgan shares rose 3.95% to $322.40 Friday, outpacing other major banks as U.S. stocks rallied and the Dow closed above 50,000 for the first time. The bank recently completed a $3 billion subordinated notes offering. Investors are watching for delayed U.S. jobs data and inflation figures next week, ahead of JPMorgan’s Feb. 23 company update.
AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

7 February 2026
AbbVie shares rose 2% to $223.43 Friday, capping a volatile week marked by earnings and drug sales scrutiny. Moody’s upgraded AbbVie’s credit rating to A2, citing strong performance in immunology and neuroscience. Investors remain focused on Skyrizi and Rinvoq growth amid rising competition and recent regulatory filings. Trading volume stayed below average, with the stock still 9% off its 52-week high.
SK hynix stock price slips into Monday after S&P upgrade, tech selloff

SK hynix stock price slips into Monday after S&P upgrade, tech selloff

7 February 2026
SK hynix shares closed at 839,000 won, down 0.36% Friday and 8% for the week, as tech stocks retreated across Asia. S&P Global Ratings upgraded the chipmaker to “BBB+” with a positive outlook, citing strong HBM sales. The KOSPI fell 1.4% Friday, ending a six-week winning streak. Traders await Monday’s Seoul open for signs of further tech weakness.
Tariffs Fail to Derail European Stock Rally as Markets Bounce Back
Previous Story

GOOGL, NVDA, PFE, NIO, JOBY: 5 Fast‑Profit Catalysts to Watch Today (Nov. 10, 2025)

Galecto (GLTO) Soars on Damora Therapeutics Acquisition and $285M Financing: IND in 2026, Proof‑of‑Concept in 2027
Next Story

Galecto (GLTO) Soars on Damora Therapeutics Acquisition and $285M Financing: IND in 2026, Proof‑of‑Concept in 2027

Go toTop